Literature DB >> 19453998

Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients.

Thijs K Hendrikx1, Jurjen H L Velthuis, Mariska Klepper, Eveline van Gurp, Annemarie Geel, Wenda Schoordijk, Carla C Baan, Willem Weimar.   

Abstract

CD4(+) CD25(bright+) FoxP3(+) regulatory T cells (Tregs) may control donor-specific allogeneic responses in kidney transplant recipients. Recent evidence demonstrated that three phenotypical Treg-subsets, naive (CCR7(+)CD45RO(-)), central-memory (CCR7(+)CD45RO(+)) and effector-memory (CCR7(-)CD45RO(+)), are essential for the development and function of antigen-specific suppression in the lymphoid and peripheral tissues. Also, it has been appreciated that Tregs are affected by immunosuppressive agents. In clinical practice, however, the effect of a single drug remains to be determined. Therefore, we analyzed the effect of several immunosuppressive agents on the number, phenotype and function of peripheral Tregs from 46 stable kidney transplant recipients. These patients were converted to monotherapy with tacrolimus (n = 15), rapamycin (n = 17) or mycophenolate mofetil (n = 14). Blood was obtained at inclusion and 6 months thereafter. The number of Tregs increased significantly in patients on monotherapy with rapamycin (P < 0.001), which was caused by increased numbers of Tregs with a central-memory and an effector-memory phenotype (both P < 0.05). At 6 months after conversion, however, the suppressive function of Tregs did not significantly change in co-cultures stimulated with donor-Ag. Therefore, monotherapy with rapamycin allows the signals that are needed to increase the number of functional Tregs with a memory phenotype, thereby enhancing the potential capacity to regulate donor-specific responses in the lymphoid and the peripheral tissues.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19453998     DOI: 10.1111/j.1432-2277.2009.00890.x

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  24 in total

1.  Monitoring of CD4+CD25highIL-7Rαhigh activated T cells in kidney transplant recipients.

Authors:  Laure Vallotton; Karine Hadaya; Jean-Pierre Venetz; Leo H Buehler; Donatella Ciuffreda; Ghaleb Nseir; Laura Codarri; Jean Villard; Giuseppe Pantaleo; Manuel Pascual
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-14       Impact factor: 8.237

Review 2.  Recent advances in CD8+ regulatory T cell research.

Authors:  Yating Yu; Xinbo Ma; Rufei Gong; Jianmeng Zhu; Lihua Wei; Jinguang Yao
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

Review 3.  Post-transplantation malignancies: here today, gone tomorrow?

Authors:  Edward K Geissler
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

4.  Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer.

Authors:  K Singh; L Stempora; R D Harvey; A D Kirk; C P Larsen; B R Blazar; L S Kean
Journal:  Am J Transplant       Date:  2014-10-30       Impact factor: 8.086

5.  Rapamycin generates graft-homing murine suppressor CD8(+) T cells that confer donor-specific graft protection.

Authors:  Basset El Essawy; Prabhakar Putheti; Wenda Gao; Terry B Strom
Journal:  Cell Transplant       Date:  2011-03-25       Impact factor: 4.064

6.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.

Authors:  Claudio G Brunstein; Jeffrey S Miller; Qing Cao; David H McKenna; Keli L Hippen; Julie Curtsinger; Todd Defor; Bruce L Levine; Carl H June; Pablo Rubinstein; Philip B McGlave; Bruce R Blazar; John E Wagner
Journal:  Blood       Date:  2010-10-15       Impact factor: 22.113

Review 7.  Therapeutic manipulation of immune tolerance in allergic disease.

Authors:  Mübeccel Akdis; Cezmi A Akdis
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

8.  Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy.

Authors:  Joanna Hester; Natalie Mills; Sushma Shankar; Manuela Carvalho-Gaspar; Peter Friend; Kathryn J Wood
Journal:  Transplantation       Date:  2011-04-15       Impact factor: 4.939

Review 9.  CD4+ regulatory T cells in solid organ transplantation.

Authors:  Fadi Issa; Kathryn J Wood
Journal:  Curr Opin Organ Transplant       Date:  2010-12       Impact factor: 2.640

10.  Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells.

Authors:  Cristiano Scottà; Giorgia Fanelli; Sec Julie Hoong; Marco Romano; Estefania Nova Lamperti; Mitalee Sukthankar; Giuliana Guggino; Henrieta Fazekasova; Kulachelvy Ratnasothy; Pablo D Becker; Behdad Afzali; Robert I Lechler; Giovanna Lombardi
Journal:  Haematologica       Date:  2015-10-15       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.